Treatment of recurrent symptomatic ventricular tachycardia.
Eleven consecutive patients with recurrent ventricular arrhythmias were treated by an aggressive protocol and followed up prospectively. Arrhythmias, symptoms, and cardiac lesions were defined. Antiarrhythmic drugs were given on schedule, with blood levels determining dose; success or failure was defined by elimination or recurrence of symptomatic arrhythmias. When drug therapy failed, left ventricular aneurysmectomy was done when appropriate. Recurrent ventricular tachycardia was most frequently responsible for symptoms; coronary artery disease was the most frequent underlying disease. Symptomatic arrhythmias were eliminated in 8 of 11 patients (5 with drugs and 3 with aneurysmectomies), with a 16.5-month symptom-free average follow-up. An average of 2.9 therapeutic trials per patient was needed to control symptomatic arrhythmias. The average time from entry into the study until the start of ultimately effective therapy was 18 days. Therapy that eliminated symptoms did not eliminate all premature ventricular contractions, and occasionally even brief asymptomatic episodes of ventricular tachycardia persisted. Recurrent symptomatic ventricular arrhythmias can be controlled in many patients by rigorous application of current therapies.
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000150:complications; D003327:Coronary Disease / Q000150:complications; D004341:Drug Evaluation; D005260:Female; D006322:Heart Aneurysm / Q000150:complications / Q000601:surgery; D006432:Hemochromatosis / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011342:Procainamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011802:Quinidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D013610:Tachycardia / Q000188:drug therapy* / Q000209:etiology
D000889:Anti-Arrhythmia Agents; D010672:Phenytoin; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide